Navigation Links
Abbott’s Laboratories R&D Capabilities Questione

Abbott Laboratories shares fell by 1.3% to close at $43.80 following U.S. Food and Drug Administration (FDA) rejection of its new drug Xinlay. Increased number of scientists and analysts question the efficiency of Abbott’s R&D // , after the rejection of its drug.

The drug that is to be used for the treatment of Prostate cancer failed in its Phase III trial leading to disapproval of the drug by the FDA Panel. Though Abbott is confident of its R&D capabilities and is sure of its other products like Humira, which is used in the treatment of Rheumatoid arthritis and its new drug eluting stent to be approved by the FDA, critics point out that Abbott is not winning in its R&D division as it is doing in Marketing. As FDA as put stringent and tough rules against approval of new drugs following the awful effects of the painkiller drug, Vioxx produced by Merck.

Mike Barr of Victory Capital Management said that, "What's a little disturbing is that Abbott's R&D productivity hasn't been all that great the last few years and looking at the history, they do a very good job at marketing, and it doesn't seem like R&D is up to the same caliber as their marketing." Victory Capital Management owns the shares of Abbott. Another Shareholder of Abbott is The Fifth Third Asset Management, this company is also not happy with Abbott and Mr. Jon Fisher of the company reported that, “It's evident as far as the absolute growth and profitability out of that business and I don't judge by the number of failures, but by the number of successes and how successful they are compared to their pharma peers. They're definitely on the lower end.

Glenn Novarro analyst in Banc of America Securities is optimistic about R&D of Abbott and said that though Xinlay may be a failure its other products in the pipeline like drugs Humira, Simdax, Febuxostat, drug eluting stent and Glucose monitor may succeed. "What is disappointing is that Abbott took a very aggressive approach with t his drug," by filing without a successful Phase III trial, Novarro said. "They clearly made a poor decision." He added, however, that in Abbott's defense, the company isn't a cancer specialist. "They're trying to break into the field, so it's not surprising there would be a stumble along the way."


'"/>




Related medicine news :

1. Dr Reddy’s Laboratories to challenge patents on drug
2. Dr Reddy’s Laboratories launches Hyalosy
3. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
4. Abbott Laboratories to buy Biocompatibles cardiovascular stent business
5. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
6. ICMR to Set up Laboratories to Combat Bird Flu
7. Ranbaxy Laboratories to Be Aided in Drug Research
8. Bangladesh to Set Up HIV/AIDS Diagnosis Laboratories
9. Drug Addicts To Prove ‘Child-Caring Capabilities’ By Clearing Drug Tess
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/24/2017)... , ... March 24, 2017 , ... ... Society (ONS) wanted to create a communications platform that positions them as the ... Elliance and ONS reinvented their online publication as an always-on, always-fresh news, views ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro ... their partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is ... Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation ... and college Bible teacher residing in North Carolina with his wife, Anna Marie. He ... them with six grandchildren. David is also the author of “Shadow and Substance.” , ...
(Date:3/23/2017)... ... 2017 , ... The physicians of KSF Orthopaedic Center PA are proud to ... location is located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 ... provide patients living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The MBI “Hall of Fame” recognizes the ... acts have had a significant impact on the careers of all others involved. ... Inc. was inducted into the MBI’s Hall of Fame. The induction took place during ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Research and Markets has announced the ... Strategies" report to their offering. ... Pain Management in the ... their physical pain, emphasizing consumer survey analysis, including trends over ... adults who have selected illnesses/conditions strongly associated with physical pain ...
(Date:3/24/2017)... 24, 2017 ShangPharma, a leading ... cost-effective drug development and discovery services, technology, ... industry, announced today the intent for a ... be consolidating the Contract Research Organizations (CRO) ... ChemPartner. These entities include ChemPartner Shanghai, ChemPartner ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
Breaking Medicine Technology: